Skip to main content

4 Result(s)

within Douglas B. Fox Remove this filter

and

  1. Article

    Open Access

    Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade

    Immune checkpoint blockade (ICB) has demonstrated efficacy in patients with melanoma, but many exhibit poor responses. Using single cell RNA sequencing of melanoma patient-derived circulating tumor cells (CTCs...

    Douglas B. Fox, Richard Y. Ebright, **n Hong, Hunter C. Russell… in npj Precision Oncology (2023)

    Download PDF (1311 KB) View Article

  2. No Access

    Article

    Evaluation of endocrine resistance using ESR1 genoty** of circulating tumor cells and plasma DNA

    Therapeutic efficacy of hormonal therapies to target estrogen receptor (ER)-positive breast cancer is limited by the acquisition of ligand-independent ESR1 mutations, which confer treatment resistance to aromatas...

    Tilak K. Sundaresan, Taronish D. Dubash… in Breast Cancer Research and Treatment (2021)

  3. Article

    Open Access

    Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence

    The survival and recurrence of residual tumor cells following therapy constitutes one of the biggest obstacles to obtaining cures in breast cancer, but it remains unclear how the clonal composition of tumors c...

    Andrea Walens, Jiaxing Lin, Jeffrey S. Damrauer, Brock McKinney… in Nature Communications (2020)

    Download PDF (3116 KB) View Article

  4. No Access

    Article

    NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism

    The survival and recurrence of dormant tumour cells following therapy is a leading cause of death in patients with cancer. The metabolic properties of these cells are likely to be distinct from those of rapidl...

    Douglas B. Fox, Nina Marie G. Garcia, Brock J. McKinney, Ryan Lupo… in Nature Metabolism (2020)